Carregando empresa
Keep exploring
The themes Novo Nordisk A/S is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
The theme it is part of
Highest-graded in Drug Manufacturers General
Graded A or B and worth $2B or more: A first, then the largest.
LLYELI Lilly And CompanyUS$ 1,36TA+
JNJJohnson & JohnsonUS$ 688,6BA+
MRKMerck & Co., Inc.US$ 364,3BA
NVSNovartis AGUS$ 306,3BA
AMGNAmgen Inc.US$ 251,9BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 de out. de 2026CBGraded C, now B
MCKMckesson Corporation4 de nov. de 2026BAGraded B, now A
CVSCVS Health Corp4 de nov. de 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 de nov. de 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 de out. de 2026CAGraded C, now A
Como ganha dinheiro
- Sales of prescription medicines for diabetes, obesity and other conditions
Concorre com
O que vende3
Wegovy injection
An injectable semaglutide medicine used for weight management.
Wegovy pill
A once-daily semaglutide pill used for weight management.
Ozempic
An injectable semaglutide medicine for type 2 diabetes.
Quem compra3
- People with diabetes or obesity who obtain medicines through a prescription or buy them directly in self-pay channels.
- Pharmacies and telehealth providers that supply medicines to patients.
- Private insurers and public programs that cover prescription medicines, including Medicare Part D in the United States.
Em que se apoia e o que pode quebrá-lo
Do que o negócio depende
- 1Recent sales growth and product launches rely on glucagon-like peptide-1 (GLP-1) medicines, including semaglutide brands such as Wegovy and Ozempic.
- 2Access to obesity medicines in the United States depends on insurance coverage and what patients can afford to pay themselves; the company said most Wegovy pill prescriptions there were self-pay in Q2 2026.
- 3Commercial supply depends on manufacturing capacity; the company said its new active pharmaceutical ingredient facilities were contributing very little commercial supply in Q2 2026.
O que pode dar errado
- 1Competition and lower realized prices can reduce sales from obesity and diabetes medicines; the company cited intensifying United States competition and pricing pressure in Q2 2026.
- 2Generic versions of semaglutide can reduce sales where patent protection expires; the company reported early generic entries in some international markets.
- 3Cybersecurity breaches could disrupt the business.
Demonstrações financeiras completas →
Sobre a Novo Nordisk A/S
Novo Nordisk makes medicines for diabetes and obesity, including Wegovy for weight management and Ozempic for type 2 diabetes. Its medicines reach patients through healthcare providers and pharmacies, with payment coming from insurers and public health programs or directly from patients. It also develops medicines for other conditions, including rare diseases.
- Sede
- Bagsværd, Denmark
- Fundada em
- 1923
- Funcionários
- around 66,700 (Q2 2026, medium)
- Listada em
- New York Stock Exchange
- Fim do exercício
- December 31
Construído a partir dos próprios documentos de Novo Nordisk A/S entregues à Comissão de Valores Mobiliários dos EUA (SEC). Os números são os divulgados, com o histórico por ação recalculado para a base de ações de hoje. Esta empresa divulga em DKK. Os números são convertidos para dólares a US$ 1,00 = 6,7640 DKK, a taxa atual, aplicada igualmente a todos os períodos — assim o crescimento e as margens são da empresa e não do câmbio. Isto descreve um negócio — não é recomendação de investimento nem sugestão de compra ou venda.
